Podcasts

HCC - New Paradigms in Management

Join Dr. Robert Wong, from Stanford University, Dr. Laura Kulik, from Northwestern, and Dr. Parissa Tabrizian, from Mount Sinai, for an expert discussion on hepatocellular carcinoma (HCC) and the evolving treatment landscape. This high-impact conversation explores how immune checkpoint inhibitors have transformed first-line systemic therapy for HCC, the integration of local regional treatments like Y90 radioembolization, and the growing role of combination strategies, including immunotherapy plus TACE or TKIs. The panel dives into personalized approaches to HCC management, including novel biomarkers, radiomics, and future applications of AI and ctDNA for better patient stratification.

The discussion also highlights expanding liver transplant eligibility through downstaging protocols and the safe use of immunotherapy in pre-transplant settings, as well as the resurgence of living donor liver transplantation. Plus, hear insights into the challenges of post-resection adjuvant therapy and the future of clinical trials in bridging systemic and curative-intent therapies. A must-watch for hepatologists, transplant surgeons, oncologists, and liver disease specialists aiming to stay at the forefront of HCC innovation.